Bulevirtide: First Approval

Bulevirtide (Hepcludex ® ), a first-in-class entry inhibitor, is being developed by MYR GmbH for the treatment of chronic hepatitis delta virus (HDV) and chronic hepatitis B virus (HBV) infections. Bulevirtide was recently approved in the European Union (EU) for the treatment of chronic HDV infectio...

Full description

Saved in:
Bibliographic Details
Published in:Drugs (New York, N.Y.) N.Y.), 2020-10, Vol.80 (15), p.1601-1605
Main Authors: Kang, Connie, Syed, Yahiya Y.
Format: Article
Language:English
Subjects:
AdisInsight Report
Antigens
Antiviral drugs
Bile
Chronic infection
Clinical trials
Drug dosages
Hepatitis
Hepatitis B
Infections
Internal Medicine
Liver cirrhosis
Liver diseases
Medicine
Medicine & Public Health
Pharmacokinetics
Pharmacology/Toxicology
Pharmacotherapy
Ribonucleic acid
RNA
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Bulevirtide (Hepcludex ® ), a first-in-class entry inhibitor, is being developed by MYR GmbH for the treatment of chronic hepatitis delta virus (HDV) and chronic hepatitis B virus (HBV) infections. Bulevirtide was recently approved in the European Union (EU) for the treatment of chronic HDV infection in HDV RNA positive adult patients with compensated liver disease. This article summarizes the milestones in the development of bulevirtide leading to this first approval for chronic HDV.
ISSN:0012-6667
1179-1950
DOI:10.1007/s40265-020-01400-1